Estudio del genoma y del transcriptoma en las fases evolutivas de las gammapatías monoclonales
type: CreativeWork
description: [EN] Epidemiological studies have shown that virtually all multiple myeloma are preceded by a premalignant phase. In this regard, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (MMQ) are considered premalignant and asymptomatic entities differ significantly in the rate of progression to symptomatic MM. Despite their radically different clinical behavior, the three entities share the same neoplastic cell apparently, which is a plasma cell (PC) and aberrant clonal. Cytogenetics and fluorescence in situ hybridization (FISH) have failed to identify abnormalities characteristic of each developmental stage. However, this could be due to either the lack of a specific genetic stamp of each developmental stage of monoclonal gammopathies, or they have not been used and the analysis tools suitable for your search. Therefore, the combination of classical cytogenetic techniques as HISF advanced genomic techniques and high resolution for exploring the status of the genome and transcriptome, could be decisive when further genetic mechanisms that trigger the transformation of premalignant entities to active MM. Furthermore, in the developmental stages of monoclonal gammopathies exists an intermediate entity between MGUS and MM is the MMQ, characterized by a risk of progression to symptomatic myeloma approximately ten times greater than the GMSI. Within the MMQ defined a group at high risk of progression to symptomatic MM (MMQ-AR). The standard treatment is abstinence MMQ to progression to symptomatic MM. Our group is leading a clinical trial (QuiReDex) to determine whether treatment with lenalidomide plus dexamethasone (LenDex) MMQ-AR in prolonging the time to progression. The opportunity to study the genome and transcriptome of a unique group of patients carefully defined from the clinical point of view, could help determine if there are genetic basis justifying a different clinical outcome in these patients. Finally, treatment of patient…
abstract: [EN] Epidemiological studies have shown that virtually all multiple myeloma are preceded by a premalignant phase. In this regard, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (MMQ) are considered premalignant and asymptomatic entities differ significantly in the rate of progression to symptomatic MM. Despite their radically different clinical behavior, the three entities share the same neoplastic cell apparently, which is a plasma cell (PC) and aberrant clonal. Cytogenetics and fluorescence in situ hybridization (FISH) have failed to identify abnormalities characteristic of each developmental stage. However, this could be due to either the lack of a specific genetic stamp of each developmental stage of monoclonal gammopathies, or they have not been used and the analysis tools suitable for your search. Therefore, the combination of classical cytogenetic techniques as HISF advanced genomic techniques and high resolution for exploring the status of the genome and transcriptome, could be decisive when further genetic mechanisms that trigger the transformation of premalignant entities to active MM. Furthermore, in the developmental stages of monoclonal gammopathies exists an intermediate entity between MGUS and MM is the MMQ, characterized by a risk of progression to symptomatic myeloma approximately ten times greater than the GMSI. Within the MMQ defined a group at high risk of progression to symptomatic MM (MMQ-AR). The standard treatment is abstinence MMQ to progression to symptomatic MM. Our group is leading a clinical trial (QuiReDex) to determine whether treatment with lenalidomide plus dexamethasone (LenDex) MMQ-AR in prolonging the time to progression. The opportunity to study the genome and transcriptome of a unique group of patients carefully defined from the clinical point of view, could help determine if there are genetic basis justifying a different clinical outcome in these patients. Finally, treatment of patient…
author: López Corral, Lucía
keywords: mieloma múltiple, Tesis y disertaciones académicas, Universidad de Salamanca (España), Academic dissertations, Citogenética, Hematología, cytogenetic, Hematology
date published: 2012
date modified: 2026-07-27T21:00:10Z
provider: Universidad de Salamanca
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: Universidad de Salamanca

PropertyValue
property ID: DOI
value: 10.14201/gredos.121186